OSTX · OS Therapies Inc
$1.53
+0.03 (+2.00%)
At close · Jul 17
Going-concern doubt
— flagged May 18, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the unaudited consolidated financial statements are issued.”View the 10-Q filed May 18, 2026
Market Cap
$68.14M
Shares
44,538,106
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Paul A. Romness | CEO | $3,434,316 |
| Robert G. Petit | Chief Medical Officer and Chief Scientific Officer | $665,046 |
| Christopher P. Acevedo | CFO | $158,523 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Paul A. Romness | CEO | $360,000 |
| Robert G. Petit | Chief Medical Officer and Chief Scientific Officer | $300,000 |
| Christopher P. Acevedo | CFO | $36,000 |